225 related articles for article (PubMed ID: 27537326)
21. Coxibs Refocus Attention on the Cardiovascular Risks of Non-Aspirin NSAIDs.
Thomas D; Ali Z; Zachariah S; Sundararaj KGS; Van Cuyk M; Cooper JC
Am J Cardiovasc Drugs; 2017 Oct; 17(5):343-346. PubMed ID: 28353025
[TBL] [Abstract][Full Text] [Related]
22. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.
Dajani EZ; Islam K
J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():117-33. PubMed ID: 18812633
[TBL] [Abstract][Full Text] [Related]
23. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
Valat JP; Deray G; Héloire F
Presse Med; 2006 Sep; 35 Suppl 1():25-34. PubMed ID: 17870550
[TBL] [Abstract][Full Text] [Related]
24. Network Meta-Analysis Comparing Relatively Selective COX-2 Inhibitors Versus Coxibs for the Prevention of NSAID-Induced Gastrointestinal Injury.
Yang M; Wang HT; Zhao M; Meng WB; Ou JQ; He JH; Zou B; Lei PG
Medicine (Baltimore); 2015 Oct; 94(40):e1592. PubMed ID: 26448006
[TBL] [Abstract][Full Text] [Related]
25. Selective COX-2 inhibitors and risk of thromboembolic events - regulatory aspects.
Heim HK; Broich K
Thromb Haemost; 2006 Oct; 96(4):423-32. PubMed ID: 17003918
[TBL] [Abstract][Full Text] [Related]
26. Update on cyclooxygenase inhibitors: has a third COX isoform entered the fray?
Hersh EV; Lally ET; Moore PA
Curr Med Res Opin; 2005 Aug; 21(8):1217-26. PubMed ID: 16083531
[TBL] [Abstract][Full Text] [Related]
27. COXIBs, CINODs and H₂S-releasing NSAIDs: current perspectives in the development of safer non steroidal anti-inflammatory drugs.
Fiorucci S; Distrutti E
Curr Med Chem; 2011; 18(23):3494-505. PubMed ID: 21756233
[TBL] [Abstract][Full Text] [Related]
28. Gastrointestinal safety of novel nonsteroidal antiinflammatory drugs: selective COX-2 inhibitors and beyond.
Coruzzi G; Venturi N; Spaggiari S
Acta Biomed; 2007 Aug; 78(2):96-110. PubMed ID: 17933277
[TBL] [Abstract][Full Text] [Related]
29. Rofecoxib-induced hepatotoxicity: a forgotten complication of the coxibs.
Yan B; Leung Y; Urbanski SJ; Myers RP
Can J Gastroenterol; 2006 May; 20(5):351-5. PubMed ID: 16691302
[TBL] [Abstract][Full Text] [Related]
30. [Is there a future for COX-2 inhibitors?].
Yodfat Y
Harefuah; 2004 Nov; 143(11):820-4, 837. PubMed ID: 15603272
[TBL] [Abstract][Full Text] [Related]
31. Systematic review: coxibs, non-steroidal anti-inflammatory drugs or no cyclooxygenase inhibitors in gastroenterological high-risk patients?
Nielsen OH; Ainsworth M; Csillag C; Rask-Madsen J
Aliment Pharmacol Ther; 2006 Jan; 23(1):27-33. PubMed ID: 16393277
[TBL] [Abstract][Full Text] [Related]
32. Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic anti-inflammatory drugs? Arguments in favor.
Mukherjee D
Thromb Haemost; 2006 Oct; 96(4):407-12. PubMed ID: 17003915
[TBL] [Abstract][Full Text] [Related]
33. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis.
Chan CC; Reid CM; Aw TJ; Liew D; Haas SJ; Krum H
J Hypertens; 2009 Dec; 27(12):2332-41. PubMed ID: 19887957
[TBL] [Abstract][Full Text] [Related]
34. Do selective COX-2 inhibitors increase the risk of cerebrovascular events? A meta-analysis of randomized controlled trials.
Chen LC; Ashcroft DM
J Clin Pharm Ther; 2006 Dec; 31(6):565-76. PubMed ID: 17176361
[TBL] [Abstract][Full Text] [Related]
35. The novel anti-inflammatory agent VA694, endowed with both NO-releasing and COX2-selective inhibiting properties, exhibits NO-mediated positive effects on blood pressure, coronary flow and endothelium in an experimental model of hypertension and endothelial dysfunction.
Martelli A; Testai L; Anzini M; Cappelli A; Di Capua A; Biava M; Poce G; Consalvi S; Giordani A; Caselli G; Rovati L; Ghelardini C; Patrignani P; Sautebin L; Breschi MC; Calderone V
Pharmacol Res; 2013 Dec; 78():1-9. PubMed ID: 24083950
[TBL] [Abstract][Full Text] [Related]
36. The COXIB experience: a look in the rearview mirror.
Marnett LJ
Annu Rev Pharmacol Toxicol; 2009; 49():265-90. PubMed ID: 18851701
[TBL] [Abstract][Full Text] [Related]
37. COX-2 inhibitors and the heart: are all coxibs the same?
Sooriakumaran P
Postgrad Med J; 2006 Apr; 82(966):242-5. PubMed ID: 16597810
[TBL] [Abstract][Full Text] [Related]
38. Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs.
Hermann M; Ruschitzka F
Ann Med; 2007; 39(1):18-27. PubMed ID: 17364448
[TBL] [Abstract][Full Text] [Related]
39. Cardiovascular effects of coxibs.
Caporali R; Montecucco C
Lupus; 2005; 14(9):785-8. PubMed ID: 16218488
[TBL] [Abstract][Full Text] [Related]
40. NSAID-induced gastrointestinal damage: current clinical management and recommendations for prevention.
Lanas A; Ferrandez A
Chin J Dig Dis; 2006; 7(3):127-33. PubMed ID: 16808792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
